Clinical trials
catalyst calendar across sponsors →Studies where SPRY is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
5 interventional · 2 with posted results
Held by 13 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, Third Point LLC, CITADEL ADVISORS LLC, MARSHALL WACE, LLP, Balyasny Asset Management L.P., +8 more) · FINRA short interest 7.8 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 2 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous UrticariaNCT06927999Determine the effect of ARS-2 (0.5 mg or 1 mg) versus placebo on itch and hiveRandomized · Double-masked · Treatment | Phase 2 | Recruiting | Drug: Placebo, 0.5 mg epinephrine, 1 mg epinephrine | Urticaria Chronic | 42 | Jun 2027 | ≤ 315 d | 2026-07-22 |
| Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen ImmunotherapyNCT06834165AEs after epinephrine treatment within 2 hoursRandomized · Open-label · Treatment | Phase 4 | Recruiting | Drug: Neffy, Adrenaline | Allergic Reactions | 600 | Apr 2027 | ≤ 254 d | 2026-04-21 |
| Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria FlaresNCT05496465results2026-04-07Effect of ARS-1 Versus Placebo Based on a Patient Reported Pruritus/Hive ScoreRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: ARS-1 | Urticaria | 21 | 2024-02-29actual | — | 2026-04-07 |
| Administration of ARS-1 or Albuterol in Subjects With Persistent AsthmaNCT05363670results2026-07-14Effect of ARS-1 Versus Albuterol and PlaceboRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: ARS-1 1 mg, Albuterol MDI, Placebo, ARS-1 2mg | Asthma | 18 | 2024-02-02actual | — | 2026-07-14 |
| Pharmacokinetics of Adrenaline After Administration of ARS -1 in Subjects With Upper Respiratory Tract InfectionNCT04930900To evaluate the bioavailability (Cmax) of ARS-1 after intranasal administrationNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: ARS-1 with URTI, ARS-1 without URTI | Upper Respiratory Tract Infection | 15 | 2022-03-31actual | — | 2022-07-29 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19